The Nijhawan and De Brabander labs merged to jointly deploy our expertise in synthetic and medicinal chemistry, small molecule pharmacology, biochemistry, and genetics to accelerate the process of discovering the target(s) of orphan small molecules with interesting phenotypes. We focus both on biochemical and state-of-the-art forward genetics systems and developed a streamlined target identification platform that overcomes many of the challenges associated with traditional target ID. Ultimately, our integrated deorphanization approach provides fully characterized chemical probes that lead to novel insights into biology and provides translational opportunities relevant to human disease.